What was the main driver for the decrease in net income and EPS compared to the prior year?

The primary reason for the significant decrease in net income and earnings per share was a $115 million charge for acquired in-process research and development related to the acquisition of TriPath Imaging, Inc. This charge, while impacting reported profitability, is associated with investments in future growth areas.

How did the acquisition of TriPath Imaging affect the company's business segments?

The acquisition of TriPath Imaging, Inc. was a strategic move to enhance BDX's position in cancer diagnostics. It was integrated into the Diagnostics Segment, contributing to revenue growth in that area and advancing the company's capabilities in disease detection, diagnosis, staging, and treatment management.

What was the financial impact of divesting the Blood Glucose Monitoring (BGM) product line?

BDX sold its BGM product line for $20 million, recognizing a pre-tax gain of $15 million. This divestiture simplifies the company's business focus and allows for greater allocation of resources to core growth areas.

What is the company's outlook on revenue growth and profitability for the upcoming year?

BDX anticipates continued revenue growth driven by expansion in all segments and the development of new, higher-margin products. The company also expects gross profit margin to improve by approximately 70 basis points in fiscal 2007, partly due to the inclusion of TriPath operations. However, selling and administrative expenses are expected to increase slightly due to acquisitions and inflation.

BDX 10-Q Quarterly Report Q1 FY2007 — Revenue, Net Income, EPS

Summary

Becton Dickinson & Co. (BDX) reported its fiscal first quarter 2007 results for the period ending December 30, 2006. The company demonstrated solid revenue growth of 8% year-over-year, reaching $1.502 billion, driven by strong performance in its Medical and Biosciences segments, as well as favorable foreign currency translation. Despite a significant year-over-year decrease in net income and earnings per share, largely due to a substantial $115 million charge for acquired in-process research and development related to the TriPath acquisition, the underlying operational performance remained robust. The company highlighted continued investment in innovation and strategic acquisitions, with the acquisition of TriPath Imaging significantly bolstering its diagnostics capabilities in cancer detection. BDX also successfully divested its blood glucose monitoring (BGM) product line, recognizing a gain on sale and simplifying its business. The company's balance sheet remains strong, with a decreasing debt-to-capitalization ratio, and it continues to return value to shareholders through share repurchases and dividends.

Key Highlights

1Revenue increased by 8% to $1.502 billion, driven by volume growth and favorable foreign currency translation.
2Acquisition of TriPath Imaging, Inc. for approximately $362 million, significantly strengthening the Diagnostics segment, particularly in cancer diagnostics. This acquisition resulted in a $115 million charge for acquired in-process R&D.
3Divestiture of the Blood Glucose Monitoring (BGM) product line for $20 million, resulting in a pre-tax gain of $15 million and simplifying the company's portfolio.
4Net income decreased year-over-year from $217.9 million to $142.9 million, primarily due to the TriPath acquisition's in-process R&D charge.
5Basic Earnings Per Share (EPS) decreased from $0.88 to $0.58, with diluted EPS also declining from $0.85 to $0.56, impacted by the aforementioned acquisition charge.
6Operating income from the Medical segment increased to $246 million, and Biosciences segment operating income rose to $56 million.
7The debt-to-capitalization ratio improved to 21.9% at December 31, 2006, down from 25.8% at September 30, 2006, indicating a stronger balance sheet.

BECTON DICKINSON & CO Quarterly Report for Q1 Ended Dec 31, 2006

Summary

Key Highlights

Frequently Asked Questions